YASEMIN ARDICOGLU AKISIN

Dr. YASEMIN ARDICOGLU AKISIN

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2023 in Phoenix Medical Journal
Verified
Journal Article
Open access
GKGülnur Kul
Gülnur Kul
STSelma Tosun
Selma Tosun
SASebahat Aksaray
Sebahat Aksaray
YUYusuf Ustun
Yusuf Ustun
GEGUNAY TUNCER ERTEM
GUNAY TUNCER ERTEM
SKSibel Yildiz Kaya
Sibel Yildiz Kaya
Amaç: Toksoplazma gondii (T. gondii), Rubella ve Cytomegalovirüs (CMV)etkenlerinin neden olduğu TORCH grubu enfeksiyonları sağlıklı yetişkinlerde asemptomatik seyrederken, gebelik döneminde vertikal bulaşla fetal morbidite ve mortalite ile sonuçlanabilir. Günümüzde gebelik sırasında bu enfeksiyon etkenlerinin rutin taraması konusunda net bir fikir birliği yoktur. Çalışmamızda ülke genelinde toxoplazma gondii, rubella ve sitomegalovirus enfeksiyonlarının gebelik dönemindeki seroprevelans durumunun belirlenmesi ve diğer ülkelerin verileriyle karşılaştırılması amaçlanmıştır. Gereç ve Yöntem: Çalışma çok merkezli, retrospektif, tanımlayıcı kesitsel bir araştırma olarak planlanmıştır. Çalışmamıza 2011-19 yılları arasında, ikinci basamak devlet hastanesi, üçüncü basamak eğitim araştırma hastanesi ve üniversite hastanelerine o yıl kuruma başvuran gebe sayısı, o yıl toksoplazma, rubella ve sitomegalovirus tetkiki yapılan gebe sayısı, IgM ve IgG sonuçları ve ulaşılabilirse toksoplazma ve sitomegalovirus avidite test sonuçları kaydedilmiştir. Rubella IgG negatif olan hastaların yaşları dahil edilmiştir. Bulgular: Türkiye’nin on farklı ilindeki ikinci ve üçüncü basamak sağlık kuruluşlarından toplam 15 merkezin katıldığı bu çalışmada, bu merkezlere başvurmuş ve gebelik durumu olan toplam 354526 kişiden elde edilen veriler sonucunda; anti toksoplazma IgG seropozitifliği %21, anti rubella IgG seropozitifliği %96.5, anti CMV Ig G seropozitifliği %56.2 bulunmuştur. Çalışmamızda anti rubella IgG negatif gebelerin yaşları değerlendirilmiştir. Rubella IgG negatif 2024 gebenin yaş ortalaması 30.6 yıl (18-54) bulunmuştur. Yaş aralıklarına göre incelendiğinde seronegatifliğin en çok 30-39 yaş aralığında olduğu görülmüştür. Sonuç: Gebelerde toksoplazma, rubella ve sitomegalovirus enfeksiyonu sıklığı ve yaygınlığı hakkında bilgi sahibi olmak, hastalık yükünün belirlenmesinde, tarama programlarının planlanmasında ve birinci basamak sağlık hizmetlerinin aktif kullanımında kritik bir rol oynamaktadır. Aşılama ile bağışıklığın sağlanabildiği rubella enfeksiyonu için seronegatif bireylerin tespit edilip gebelik öncesi aşılanması önemlidir.

1 December 2023 in Turkish Journal of Biochemistry
Verified
Journal Article
Open access
PDF file
YAYASEMIN ARDICOGLU AKISIN
YASEMIN ARDICOGLU AKISIN
NANejat Akar
Nejat Akar
MCMert Burkay Coteli̇
Mert Burkay Coteli̇
Objectives: Epstein–Barr virus (EBV) is a member of the herpes virus that causes infectious mononucleosis (IM). Downey cell is the atypical lymphocyte of IM and can be seen in various conditions. Peripheral blood smear (PBS) microscopic evaluation is used to identify Downey cells. A lack of experienced professionals or professional errors may obstruct early and accurate diagnostics for the microscopic evaluation. The main objective of this study is to create a decision support system by digitizing the PBS samples. A general tool providing an inexpensive and measurable solution is envisioned to analyze the PBS samples in detail to give alerting flags to prevent missing Downey cells in manual analysis. Methods: The PBS dataset collected was split into Downey positives and negatives. The negative set consisted of 5 leucocyte subtypes. Mantiscope, a cloud-based slide scanner system, was used to collect images from the physical PBS samples. Clinically and laboratory-confirmed 35 IM patients and 124 healthy PBS slides were selected for this procedure. A number of cell counts were obtained after the application of annotation and augmentation methods, and a partially balanced dataset was created for the artificial intelligence (AI) network training. The verification steps included the calculation of sensitivity, specificity, and Cohen’s kappa metrics from the partitioned testing set that was not used during training. A validation process was also performed over the manually identified PBS samples to measure whether the algorithm noticed the samples or not. Results: After testing this setup, we have observed 98 % sensitivity and 99 % specificity for Downey cells. According to the validation procedure of Downey positive and negative samples that were carried out by the physicians, a sensitivity of 57 %, specificity of 100 %, and Cohen’s kappa value of 0 . 5 were observed. Besides, the accuracy was found to be 66 % according to the physicians’ evaluations employing the digital images which were identified by Mantiscope, Conclusions: Decision support systems can alert the physician for Downey cells and increase the rate of true diagnosis in PBS evaluation. A higher sensitivity and specificity for the detection of Downey cells would be achieved. However, the variance over the dataset is a constraint for effective diagnosis. As the annotation and AI development process continues to collect more data from patients, the model can be updated for future releases.

1 July 2022 in Mikrobiyoloji Bulteni
Verified
Journal Article
Closed access
FÖFerda Özyurda
Ferda Özyurda
YAYASEMIN ARDICOGLU AKISIN
YASEMIN ARDICOGLU AKISIN
TMTuğba Mert
Tuğba Mert
BPBarış Poyraz
Barış Poyraz
YÖYasemen Özkan
Yasemen Özkan
NANejat Akar
Nejat Akar
The Coronavirus disease 2019 (COVID-19) pandemic still continues around the world by making peaks with different variants. In the fight against COVID-19, vaccination is currently the only protective measure. In Turkey, vaccination started firstly in healthcare workers on 13 January 2021 with the CoronaVac (Sinovac Biotech, Chinese) vaccine, and booster doses were administered with the CoronaVac and Comirnaty vaccines in July 2021. In this cross-sectional study, it was aimed to determine the humoral and cellular immunity levels of the employees of the TOBB ETU Hospital 2.5-3.5 months after three doses of vaccination and identify the effective factors. With the power analysis that was conducted with the G*Power software, it was determined to be suitable to include 40 TOBB ETU Hospital workers who had their third dose with the CoronaVac vaccine and 60 workers of the same hospital who had their third dose with the Comirnaty (Pfizer Biontech, Germany) vaccine, and age- and sex-matching was considered by selecting 60 workers randomly from among 223 workers who had Comirnaty as their third dose. The study excluded individuals who had a previous COVID-19 infection or had a positive PCR test result. After collecting blood samples on 18-22 October 2021, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) immunoglobulin G levels were studied with the chemiluminescence immunoassay method using a Beckman-Access device (Beckman Coulter Inc., CA, USA) for humoral immunity, and T-SPOT test (T-SPOT. CO VID SARS-CoV-2 test-Oxford Immunotec, Singapur) was carried out for cellular immunity. Additionally, demographic data, habits, personal information such as weight and height, reasons for choosing the vaccine and post-vaccine side effects were obtained through the data collection form. Data collection was completed on 29 November 2021. As a result, among the healthcare workers who had received their third dose of vaccine with Comirnaty and CoronaVac; while 25% of those who received three doses of CoronaVac had humoral immunity, 93.3% humoral immunity was determined in the heterogeneous vaccine group with two doses of CoronaVac and one dose of Comirnaty vaccine (p< 0.05). Cellular immunity was found to be higher (88.3%, 70%) in those who received the heterologous vaccine than those who completed three doses of the same vaccine (p< 0.05). In the heterogeneous vaccination group consisting of the healthcare workers who had their third vaccine dose with Comirnaty and those who had it with CoronaVac, humoral and cellular immunity levels were found high. Among the participants whose humoral immunity was found negative, cellular immunity was present in 75% of those who had Comirnaty as their third dose and 63.3% of those who had CoronaVac. While no significant relationship was found between immunity levels and age, sex or body mass index (BMI), the levels of both forms of immunity were lower in those who had chronic diseases. Among the participants, physicians preferred the third dose of Comirnaty vaccine at a rate of 71.4% and laboratory workers preferred this vaccine at a rate of 80% according to the workplace. In the third dose vaccine preference reasons, it was stated that 55% would continue with the same vaccine, experience fewer side effects, 44% provide more immunity and 9% do not prevent going abroad. The incidence of side effects after the third dose of vaccine was 53% higher in those who received the Comirnaty vaccine than in those who received CoronaVac (35%). Based on these data, it was concluded that heterologous vaccination should be preferred in vaccination strategies, and knowing cellular immunity levels is important for the decision. There is a need for more comprehensive and follow-up studies on how long humoral and especially cellular immunity lasts.

1 January 2021 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Closed access
YAYASEMIN ARDICOGLU AKISIN
YASEMIN ARDICOGLU AKISIN
NANejat Akar
Nejat Akar

1 March 2019 in The Journal of Pediatric Research
Verified
Journal Article
Closed access
NANejat Akar
Nejat Akar
ZKZeynep Nur Karagöz
Zeynep Nur Karagöz
YAYASEMIN ARDICOGLU AKISIN
YASEMIN ARDICOGLU AKISIN

11 June 2019 in Turkish Journal of Hematology
Verified
Journal Article
Open access
YAYASEMIN ARDICOGLU AKISIN
YASEMIN ARDICOGLU AKISIN
NANejat Akar
Nejat Akar